Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity
المؤلفون المشاركون
Herzog, J.
Klot-Heydenfeldt, F. von
Jabar, S.
Ranft, A.
Rossig, C.
Van den Brande, J.
Luettichau, I. von
Grohar, P. J.
Berdel, W. E.
Burdach, St.
Dirksen, Uta
D'Incalci, Maurizio
المصدر
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-10-24
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Background.
Preclinical data indicate that trabectedin followed by irinotecan has strong synergistic effects on Ewing sarcoma.
This is presumably due to hypersensitization of the tumor cells to the camptothecin as an effect of trabectedin in addition to synergistic suppression of EWS-FLI1 downstream targets.
A strong effect was also reported in a human rhabdomyosarcoma xenograft.
Procedure.
Twelve patients with end-stage refractory translocation-positive sarcomas were treated with trabectedin followed by irinotecan within a compassionate use program.
Eight patients had Ewing sarcoma and four patients had other translocation-positive sarcomas.
Results.
Three-month survival rate was 0.75 after the start of this therapy.
One patient achieved a partial response according to RECIST criteria, five had stable disease, and the remaining six progressed through therapy.
The majority of patients experienced significant hematological toxicity (grades 3 and 4).
Reversible liver toxicity and diarrhea also occurred.
Conclusions.
Our experience with the combination of trabectedin followed with irinotecan in patients with advanced sarcomas showed promising results in controlling refractory solid tumors.
While the hematological toxicity was significant, it was reversible.
Quality of life during therapy was maintained.
These observations encourage a larger clinical trial.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Herzog, J.& Klot-Heydenfeldt, F. von& Jabar, S.& Ranft, A.& Rossig, C.& Dirksen, Uta…[et al.]. 2016. Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. Complexity،Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1115785
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Herzog, J.…[et al.]. Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. Complexity No. 2016 (2016), pp.1-6.
https://search.emarefa.net/detail/BIM-1115785
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Herzog, J.& Klot-Heydenfeldt, F. von& Jabar, S.& Ranft, A.& Rossig, C.& Dirksen, Uta…[et al.]. Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. Complexity. 2016. Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1115785
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1115785
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر